MADIGAN ARMY MEDICAL CENTER

2022 ANTIMICROBIAL SUSCEPTIBILITY OF COMMON ISOLATES
DEPARTMENTS OF PATHOLOGY AND PHARMACY
(253) 968-1753

* Based on data from 2021 January to December

Lists percent Susceptible, remainder are non-susceptible, resistant or intermediate

Gram Negative Organisms	# Of Isolates ^{a,b}	Amoxicillin/ Clavulanate	Ampicillin	Ampicillin/ Sulbactam	Cefazolin ^d	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Gentamicin	Imipenem	Levofloxacin	Nitrofurantoin ^e	Piperacillin/ Tazobactam	Tobramycin	Trimethoprim/ Sulfamethox.
Citrobacter koseri ^c	33	96				100			100	100	100	100	81	100	100	
Enterobacter cloacae complex ^c	38					94			97	100	88	97		89	100	100
Escherichia coli	1176	88	66	73	92 ^f	97 ^f	96 ^f	99 ^f	89	96	100	88	99	100	96	83
Klebsiella oxytoca	40			60	32	91 ^f	91 ^f	95	98	95	100	100	85	90	97	95
Klebsiella pneumoniae	146	99		89	98	95 ^f	95 ^f	95	96	100	100	96		100	100	94
Proteus mirabilis	72	86	83	96	83	96	95	96	92	97	10	92		97	100	90
Pseudomonas aeruginosa	95					100	100		98	100	100	96		100	100	
Gram Positive Organisms	# Of Isolates	Benzylpenicillin	Ciprofloxacin	Clindamycin ^{h,l}	Erythromycin ⁱ	Gentamicin synergy ⁱ	Levofloxacin	Linezolid	Nitrofurantoin ^e	Oxacillin	Streptomycin synergy ^j	Tetracycline	Trimethoprim/ Sulfamethox.	Vancomycin		
Enterococcus faecalis	122	98	92			85	92	100	100		94			100		
Staphylococcus aureus (MSSA) k	220		87	89	67		88	100	100	100		98	100	100		
Staphylococcus aureus (MRSA) k	72		37	70 ^f			32	100	100			89	89	100		
Staphylococcus lugdunensis	42		100	89	89	<u>'</u>		100	100	93		86		100		
Streptococcus agalactiae (Group B) g	30	100		48										100		

- a)Number of isolates was determined by pulling culture data from specimens collected in the JBLM footprint and (NMRTC) Bremerton
- b) Total number of organisms may not be applicable for each drug or may be less than the total listed for some drugs
- c) First and Third generation Cephalosporins not reported due to chromosomal mediated resistance AMP-C
- d) Only reported for Urine cultures due to automated linearity and breakpoint changes
- e) For use with urinary tract isolates only

Microbiology Laboratory

- f) Percent susceptibility rate primarily represent results from January-June 2021 only
- g) Susceptibility performed by special request for patients allergic to Penicillin, or from sterile sites
- h) Clindamycin results for all Staphylococcus species and Streptococcus agalactiae are confirmed by a inducible resistance test
- i) Erythromycin and Clindamycin not reported on urinary tract isolates
- j) Synergy Screen: **S** result indicates synergy with Penicillin is likely
- k) Oxacillin resistance for all Staph aureus was 25%

R result indicates synergy with Penicillin is not likely

